Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema, HAE. NTLA-2002 is a wholly owned investigational in vivo CRISPR-based therapy in development as a single-dose treatment for this potentially life-threatening disease. Intellia expects to complete enrollment in the second half of 2025 and submit a biologics license application, BLA, in 2026 to support the Company’s plans for a U.S. launch in 2027.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia ATTR, HAE studies progressing as planned, says JPMorgan
- Intellia Therapeutics price target lowered to $40 from $60 at Oppenheimer
- Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital
- Intellia Therapeutics price target lowered to $48 from $60 at Evercore ISI
- Intellia Therapeutics Restructures to Focus on Late-Stage Programs